Tectonic Therapeutic to Participate in September Investor Conferences
Tectonic Therapeutic (NASDAQ: TECX), a clinical stage biotech company focused on G-protein coupled receptors (GPCRs), has announced its participation in two major investor conferences in September 2024. The company will present at the 2024 Wells Fargo Healthcare Conference in Boston on September 4, featuring a fireside chat with CEO Alise Reicin at 3:45 PM ET. Additionally, Tectonic will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference in New York on September 6, engaging in one-on-one investor meetings.
A live webcast of the Wells Fargo conference presentation will be available on Tectonic's website, with a replay accessible for approximately 90 days. These conferences provide Tectonic with opportunities to showcase its progress in developing therapeutic proteins and antibodies that modulate GPCR activity to potential investors and industry professionals.
Tectonic Therapeutic (NASDAQ: TECX), una società biotecnologica in fase clinica focalizzata sui recettori accoppiati alle proteine G (GPCR), ha annunciato la sua partecipazione a due importanti conferenze per investitori a settembre 2024. L'azienda presenterà alla Conferenza Sanitaria Wells Fargo 2024 a Boston il 4 settembre, con un'intervista informale con l'amministratore delegato Alise Reicin alle 15:45 ET. Inoltre, Tectonic parteciperà alla 22ª Conferenza Sanitaria Globale Annuale di Morgan Stanley a New York il 6 settembre, partecipando a incontri one-to-one con gli investitori.
Una diretta web della presentazione alla conferenza Wells Fargo sarà disponibile sul sito web di Tectonic, con una registrazione accessibile per circa 90 giorni. Queste conferenze offrono a Tectonic l'opportunità di mostrare i propri progressi nello sviluppo di proteine terapeutiche e anticorpi che modulano l'attività dei GPCR a potenziali investitori e professionisti del settore.
Tectonic Therapeutic (NASDAQ: TECX), una empresa biotecnológica en etapa clínica centrada en los receptores acoplados a proteínas G (GPCR), ha anunciado su participación en dos importantes conferencias para inversores en septiembre de 2024. La compañía presentará en la Conferencia de Salud Wells Fargo 2024 en Boston el 4 de septiembre, con una charla informal con la CEO Alise Reicin a las 3:45 PM ET. Además, Tectonic participará en la 22ª Conferencia Anual de Salud Global de Morgan Stanley en Nueva York el 6 de septiembre, realizando reuniones individuales con inversores.
Una transmisión en vivo de la presentación de la conferencia de Wells Fargo estará disponible en el sitio web de Tectonic, con una grabación accesible por aproximadamente 90 días. Estas conferencias ofrecen a Tectonic la oportunidad de mostrar su progreso en el desarrollo de proteínas terapéuticas y anticuerpos que modulan la actividad de los GPCR a posibles inversores y profesionales de la industria.
Tectonic Therapeutic (NASDAQ: TECX)는 G단백질 결합 수용체(GPCR)에 중점을 둔 임상 단계의 생명공학 회사로서, 2024년 9월에 두 개의 주요 투자자 회의에 참가한다고 발표했습니다. 이 회사는 9월 4일 보스턴에서 열리는 2024 웰스파고 헬스케어 컨퍼런스에서 CEO인 알리제 레이신과의 대담을 3:45 PM ET에 진행할 예정입니다. 추가로, Tectonic은 9월 6일 뉴욕에서 열리는 모건 스탠리 제22회 연례 세계 헬스케어 컨퍼런스에도 참여하며 일대일 투자자 회의에 참석할 것입니다.
웰스파고 회의 발표의 생중계는 Tectonic의 웹사이트에서 이용 가능하며, 약 90일 동안 재생이 가능합니다. 이러한 회의는 Tectonic이 GPCR 활동을 조절하는 치료 단백질과 항체 개발에서의 진전을 잠재적 투자자와 업계 전문가에게 선보일 수 있는 기회를 제공합니다.
Tectonic Therapeutic (NASDAQ: TECX), une entreprise biopharmaceutique en phase clinique axée sur les récepteurs couplés aux protéines G (GPCR), a annoncé sa participation à deux grandes conférences pour investisseurs en septembre 2024. L'entreprise présentera lors de la 2024 Wells Fargo Healthcare Conference à Boston le 4 septembre, avec un entretien informel avec la PDG Alise Reicin à 15h45 ET. De plus, Tectonic participera à la 22ème Conférence Annuelle Mondiale de la Santé de Morgan Stanley à New York le 6 septembre, en réalisant des réunions en tête-à-tête avec des investisseurs.
Une diffusion en direct de la présentation de la conférence Wells Fargo sera disponible sur le site Web de Tectonic, avec une rediffusion accessible pendant environ 90 jours. Ces conférences offrent à Tectonic l'occasion de montrer ses progrès dans le développement de protéines thérapeutiques et d'anticorps qui modulent l'activité des GPCR à des investisseurs potentiels et à des professionnels de l'industrie.
Tectonic Therapeutic (NASDAQ: TECX), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf G-Protein-gekoppelte Rezeptoren (GPCRs) konzentriert, hat seine Teilnahme an zwei wichtigen Investorenkonferenzen im September 2024 angekündigt. Das Unternehmen wird am 4. September auf der 2024 Wells Fargo Healthcare Conference in Boston präsentieren, einschließlich eines Fireside Chats mit der CEO Alise Reicin um 15:45 Uhr ET. Zudem wird Tectonic am 6. September an der 22. jährlichen globalen Gesundheitskonferenz von Morgan Stanley in New York teilnehmen und persönliche Treffen mit Investoren durchführen.
Ein Live-Stream der Präsentation auf der Wells Fargo-Konferenz wird auf der Website von Tectonic verfügbar sein, mit einem Zugriff auf die Aufzeichnung für etwa 90 Tage. Diese Konferenzen bieten Tectonic die Möglichkeit, seine Fortschritte bei der Entwicklung therapeutischer Proteine und Antikörper, die die GPCR-Aktivität modulieren, potenziellen Investoren und Fachleuten aus der Branche zu präsentieren.
- None.
- None.
WATERTOWN, Mass., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (Tectonic), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced that company management will present at the 2024 Wells Fargo Healthcare Conference being held in Boston on September 4-6, 2024 and participate in the Morgan Stanley 22nd Annual Global Healthcare Conference being held in New York on September 4-6, 2024.
| 2024 Wells Fargo Healthcare Conference: | |
| Date: | September 4, 2024 |
| Time: | 3:45 PM ET |
| Presenter: | Alise Reicin, MD, President, CEO and Director, Tectonic Therapeutic |
| Format: | Fireside Chat |
| Morgan Stanley 22nd Annual Global Healthcare Conference: | |
| Date: | September 6, 2024 |
| Format: | Investor one-on-one meetings |
A live webcast of the fireside chat at the Wells Fargo Healthcare Conference can be accessed under “Events & Presentations” on the Investors section of the Tectonic website at www.tectonictx.com. A replay of the webcast will be available on the Company’s website for approximately 90 days.
About Tectonic
Tectonic Therapeutic is a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (“GPCRs”). Leveraging its proprietary GEODe™ (“GPCRs Engineered for Optimal Discovery”) technology platform, Tectonic is focused on developing biologic medicines that have the potential to overcome the existing challenges of GPCR-targeted drug discovery and harness the human body to modify the course of disease. Tectonic focuses on areas of significant unmet medical need, often where therapeutic options are poor or nonexistent, as these are areas where new medicines have the potential to improve patient quality or extend duration of life. Tectonic’s initial product candidate, TX000045 (TX45), is an Fc-relaxin fusion protein with optimized pharmacokinetics and biophysical properties that activates the RXFP1 receptor, the GPCR target of the hormone relaxin. TX45 is currently in a Phase 2 clinical trial and has the potential to address patients with Group 2 Pulmonary Hypertension (PH) due to Heart Failure with Preserved Ejection Fraction (PH-HFpEF), which affects over 600,000 people in the US alone, currently with no approved therapies. Tectonic is headquartered in Watertown, Massachusetts. For more information, please visit www.tectonictx.com and follow @TectonicTx on X (formerly Twitter) and LinkedIn.
Contacts:
Investors:
Dan Ferry
LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576
Media:
Karen Sharma
CG Life
ksharma@cglife.com
(617) 571-2733
FAQ
When and where will Tectonic Therapeutic (TECX) present at the Wells Fargo Healthcare Conference in 2024?
Who will represent Tectonic Therapeutic (TECX) at the Wells Fargo Healthcare Conference?
What type of participation will Tectonic Therapeutic (TECX) have at the Morgan Stanley Global Healthcare Conference?
How can investors access the webcast of Tectonic Therapeutic's (TECX) presentation at the Wells Fargo conference?
What is the main focus of Tectonic Therapeutic's (TECX) research and development?
